Is Midostaurin covered by medical insurance?

Midostaurin is a multi-target tyrosine kinase inhibitor mainly used to treat FLT3 mutant acute myeloid leukemia (AML) and systemic mastocytosis and other diseases. As a targeted therapy drug, it has been approved in many countries around the world and is widely used clinically. However, as of now, midostaurin has not been officially launched in mainland China, and therefore has not been included in the national medical insurance reimbursement catalog.

For domestic patients, if there is a clinical need to use midostaurin, they may consider obtaining the drug through legal overseas medical channels. Currently, there are multiple versions of the original drug overseas, including the European version, the Indian version, the Turkish version, etc. The prices vary greatly, with the lowest being about 20,000 yuan for a course of treatment, and the highest being up to more than 120,000 yuan. Price fluctuations are usually related to origin, specifications and supply chain channels. Since they are not yet on the market in China, the purchase costs of these drugs cannot be reimbursed by medical insurance and must be borne by the patient themselves.

In addition to the original drug, there is currently a generic version of midostaurin in the Indian market, which has received formal local marketing approval. This type of generic drugs is basically the same as the original drugs in terms of drug ingredients, efficacy and safety, and is one of the choices for some patients with greater financial pressure. Taking the packaging of 25mg*28 capsules as an example, the price of generic drugs is about 9,000 yuan, which is more cost-effective than the original drugs. However, patients are still recommended to purchase and use them rationally under the guidance of a doctor.

Generally speaking, midostaurin has not yet been included in my country's medical insurance system. If patients need to use it, they can only rely on overseas channels to purchase it, which imposes a relatively heavy financial burden. Before using such drugs, it is recommended that a professional hematologist evaluate the condition and confirm treatment indications before considering drug channels and specifications. At the same time, be sure to choose qualified drug procurement channels to ensure drug safety and therapeutic effect.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html